Grace Therapeutics, Inc.
GRCE$24M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaPRINCETON6 employees
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
GRCE News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
GTX-104
Aneurysmal Subarachnoid Hemorrhage (aSAH)
CaPre
Hypertriglyceridemia
Lipid Lowering Medication
Hypertriglyceridemia
CaPre (TM)
Hypertriglyceridemia
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
GTX-104 | Phase 3 | Aneurysmal Subarachnoid Hemorrhage (aSAH) | - | - |
CaPre | Phase 3 | Hypertriglyceridemia | - | - |
Lipid Lowering Medication | Phase 2 | Hypertriglyceridemia | - | - |
CaPre (TM) | Phase 2 | Hypertriglyceridemia | - | - |
Hypertriglyceridemia
2 drugs in this indication
Aneurysmal Subarachnoid Hemorrhage (aSAH)
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply